In addition to thyroid cancer, observational and pharmacovigilance studies have investigated potential associations between GLP-1 RA use and other malignancies—including pancreatic, colorectal, and breast cancers—with inconsistent results [13–15]. The gene discussed is GLP1R; the disease is thyroid gland carcinoma.